Fumarylacetoacetate inhibits the initial step of the base excision repair pathway: implication for the pathogenesis of tyrosinemia type I

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Inherited Metabolic Disease

• Publication date

  2013-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10545-012-9556-0PMID 23138988
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Impaired DNA repair and genomic stability in hereditary tyrosinemia type 1.

  2012cited by this paper
• Separation-of-function mutants unravel the dual-reaction mode of human 8-oxoguanine DNA glycosylase.

  2011cited by this paper
• The mouse ortholog of NEIL3 is a functional DNA glycosylase in vitro and in vivo

  2010cited by this paper
• Hereditary tyrosinemia type 1 metabolites impair DNA excision repair pathways.

  2010cited by this paper
• DNA base repair--recognition and initiation of catalysis.

  2009cited by this paper
• Targeted deletion of the genes encoding NTH1 and NEIL1 DNA N-glycosylases reveals the existence of novel carcinogenic oxidative damage to DNA.

  2009cited by this paper
• Tyrosinaemia type I—de novo mutation in liver tissue suppressing an inborn splicing defect

  2005cited by this paper
• Dissecting the Broad Substrate Specificity of Human 3-Methyladenine-DNA Glycosylase*

  2004cited by this paper
• Deficiencies in mouse Myh and Ogg1 result in tumor predisposition and G to T mutations in codon 12 of the K-ras oncogene in lung tumors.

  2004cited by this paper
• Identification and Characterization of a Novel Human DNA Glycosylase for Repair of Cytosine-derived Lesions*

  2002cited by this paper
• Identification and characterization of a human DNA glycosylase for repair of modified bases in oxidatively damaged DNA

  2002cited by this paper
• Human DNA glycosylases of the bacterial Fpg/MutM superfamily: an alternative pathway for the repair of 8-oxoguanine and other oxidation products in DNA.

  2002cited by this paper
• Cloning and characterization of a functional human homolog of Escherichia coli endonuclease III.

  1997cited by this paper
• Opposite base‐dependent reactions of a human base excision repair enzyme on DNA containing 7,8‐dihydro‐8‐oxoguanine and abasic sites

  1997cited by this paper
• The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion.

  1997cited by this paper
• Reverse chemical mutagenesis: identification of the mutagenic lesions resulting from reactive oxygen species-mediated damage to DNA.

  1994cited by this paper
• Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG

  1991cited by this paper
• The enzymatic conversion of homogentisic acid to 4-fumarylacetoacetic acid.

  1951cited by this paper
• Über die Verbreitung Eidetischer Phänomene und Ihnen Zugrunde Liegender Psychophysischer Konstitutionstypen (Reaktionstypen)

  1926cited by this paper

• A tale of two mechanisms: Clarification of the pathway for MBD4 catalyzed glycosidic bond cleavage using MD and QM/MM calculations.

  2025cites this paper
• NTBC dosing and outcomes in hereditary tyrosinemia type 1: insights from a representative human model and 99 patients

  2025cites this paper
• An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1.

  2023cites this paper
• Distinctive Formation of a DNA-Protein Cross-Link during the Repair of DNA Oxidative Damage: Insights into Human Disease from MD Simulations and QM/MM Calculations.

  2023cites this paper
• Hepatocellular carcinoma requiring liver transplantation in hereditary tyrosinemia type 1 despite nitisinone therapy and α1‐fetoprotein normalization

  2022cites this paper
• Evaluation of dynamic thiol/disulfide homeostasis in hereditary tyrosinemia type 1 patients

  2021cites this paper
• Hereditary tyrosinemia type Ⅰ: newborn screening, diagnosis and treatment.

  2021cites this paper
• Genetically blocking HPD via CRISPR-Cas9 protects against lethal liver injury in a pig model of tyrosinemia type I

  2021cites this paper
• Inhibitors of DNA Glycosylases as Prospective Drugs

  2020cites this paper
• Focus on DNA Glycosylases—A Set of Tightly Regulated Enzymes with a High Potential as Anticancer Drug Targets

  2020influential citation
• Наследственная тирозинемия 1-го типа у детей

  2019cites this paper
• Mutational spectrum of Mexican patients with tyrosinemia type 1: In silico modeling and predicted pathogenic effect of a novel missense FAH variant

  2019cites this paper
• BIOCHEMICAL AND MOLECULAR GENETIC DIAGNOSIS OF TYROSINEMIA, TYPE 1 IN RUSSIAN PATIENTS

  2019cites this paper
• Hereditary tyrosinemia type 1 in children

  2019cites this paper
• Molecular Pathogenesis of Liver Injury in Hereditary Tyrosinemia 1.

  2017cites this paper
• Genetic Discoveries Highlight Environmental Factors as Key Drivers of Liver Disease

  2017cites this paper
• Liver disease and dyslipidemia as a manifestation of lysosomal acid lipase deficiency (LAL-D). Clinical and diagnostic aspects, and a new treatment. An update.

  2017cites this paper
• Enfermedad hepática y dislipemia como manifestación de deficiencia de lipasa acida lisosomal (LAL-D): Aspectos clínicos, diagnósticos y nuevo tratamiento. Actualización

  2017cites this paper
• Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.

  2017cites this paper
• Hereditary Tyrosinemia Type I , Presentation in a Two Month Old

  2016cites this paper
• Tyrosinemia type III in an asymptomatic girl

  2015cites this paper
• Tyrosinemia type I: clinical and biochemical analysis of patients in Mexico.

  2014cites this paper